Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 15/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.45 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29919796 | 1.00 | MKNK1 (0.57) | MKNK1ROCK2AXLTLR8IRAK4 | |
| SCHEMBL28936099 | 0.85 | MKNK1 (0.56) | MKNK1ROCK2AXLIRAK4 | |
| SCHEMBL29919854 | 0.85 | MKNK1 (0.56) | MKNK1ROCK2AXLIRAK4 | |
| SCHEMBL28936211 | 0.84 | MKNK1 (0.62) | MKNK1ROCK2AXL | |
| SCHEMBL29919723 | 0.84 | MKNK1 (0.62) | MKNK1ROCK2AXL | |
| SCHEMBL28936107 | 0.84 | MKNK1 (0.57) | MKNK1ROCK2AXL | |
| SCHEMBL28936250 | 0.84 | MKNK1 (0.59) | MKNK1ROCK2AXLIRAK4 | |
| SCHEMBL29919828 | 0.84 | MKNK1 (0.59) | MKNK1ROCK2AXLIRAK4 | |
| SCHEMBL28936150 | 0.82 | MKNK1 (0.62) | MKNK1ROCK2AXL | |
| SCHEMBL28936119 | 0.82 | MKNK1 (0.66) | MKNK1ROCK2AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109020957-B | Heterocyclic compounds as MNK inhibitors | 南京天印健华医药科技有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| US-20220289719-A1 | HETEROCYCLIC COMPOUNDS AS MNK INHIBITORS | NANJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289719-A1 | HETEROCYCLIC COMPOUNDS AS MNK INHIBITORS | NIM1K, MAP3K1, MAPKAPK2 | MKNK1 28/4885ROCK2 701/4885AXL 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.